vVARDIS Holding AG
Get emails when companies you follow file: email digest settings.
Industries
What it sells; a bar is that business's share of revenue.
- dental therapeuticsSells it: a product, service or segment of its own.From the prospectus: “Our Curodont® platform includes our flagship Curodont® products—Curodont® Repair Fluoride Plus, which is currently sold in the United States and generates the vast majority of our revenues, and Curodont® Repair, which is currently sold in our other markets.”
Themes
Trends it takes part in: by selling, supplying, using or developing. A share is the revenue of the lines that are mostly that theme.
- dental cariesSells it: a product, service or segment of its own.From the prospectus: “Our proprietary peptide-enabled technology platform, Curodont®, delivers an early therapeutic solution for tooth decay, the world’s most prevalent non-communicable disease, addressing a massive global healthcare need that has historically lacked effective early-intervention medical treatment options.”
Exposures
Outside forces the filing says could move its results.
- healthcare reimbursementNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “Reimbursement may be limited for minimally invasive treatments.”All companies in healthcare reimbursement →
- foreign exchangeNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “VVVV does not hedge foreign-exchange risk.”All companies in foreign exchange →
Also named, as in many 10-Ks:
- customer concentrationNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “Customer concentration is material: one customer represented $6.7M, or 93%, of accounts receivable at June 30, 2026, compared with $1.7M, or 51%, at June 30, 2025.”
- regulatory licensingNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “Products face differing FDA, EU MDR and Swiss requirements, including clinical evidence, quality systems and post-market surveillance.”
- supplier concentrationNamed in the filing as something outside the company that could move its results.From our summary of the prospectus: “VVVV relies on third parties for peptide materials and manufacturing, sterilization, packaging, assembly, warehousing and logistics; a single counterparty supports certain key manufacturing activities.”
From the IPO prospectus (424B4) filed Nov 16, 2026, before the company's first 10-K.
No filings match these filters.